Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies.

IF 3.7 3区生物学 Q1 BIOCHEMICAL RESEARCH METHODS

Biological Procedures Online Pub Date : 2025-07-10 DOI:10.1186/s12575-025-00287-0

Xiaoyu Yang, Bin Luo, Jianhui Tian, Yanhong Wang, Xinyi Lu, Jian Ni, Yun Yang, Lei Jiang, Shengxiang Ren

{"title":"Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies.","authors":"Xiaoyu Yang, Bin Luo, Jianhui Tian, Yanhong Wang, Xinyi Lu, Jian Ni, Yun Yang, Lei Jiang, Shengxiang Ren","doi":"10.1186/s12575-025-00287-0","DOIUrl":null,"url":null,"abstract":"<p><p>Lung cancer remains the leading cause of cancer related deaths worldwide. Immunotherapy and combination therapies, involving chemotherapy, radiotherapy, and tumor anti-angiogenesis therapy, have shown promising clinical results and are expected to become a key approach in the future management of lung cancer. However, due to immune resistance, immunotherapy remains highly effective in only a subset of patients, while many others either do not respond initially or develop resistance over time. Moreover, immune-related adverse events induced by immunotherapy, further complicate treatment outcomes and prognosis. Immune-related biomarkers and ImmuneScores have driven the development of personalized immunotherapy strategies for lung cancer, and they can aid in predicting immune resistance, and forecasting immune-related adverse events (irAEs). This review summarizes the prognosis value of immune-related biomarkers and ImmuneScores in immunotherapy and combination therapies for lung cancer. The aim is to provide a foundation for personalized treatment and management of lung cancer, while offering guidance for future research directions in immunotherapy.</p>","PeriodicalId":8960,"journal":{"name":"Biological Procedures Online","volume":"27 1","pages":"25"},"PeriodicalIF":3.7000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243280/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biological Procedures Online","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1186/s12575-025-00287-0","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

Lung cancer remains the leading cause of cancer related deaths worldwide. Immunotherapy and combination therapies, involving chemotherapy, radiotherapy, and tumor anti-angiogenesis therapy, have shown promising clinical results and are expected to become a key approach in the future management of lung cancer. However, due to immune resistance, immunotherapy remains highly effective in only a subset of patients, while many others either do not respond initially or develop resistance over time. Moreover, immune-related adverse events induced by immunotherapy, further complicate treatment outcomes and prognosis. Immune-related biomarkers and ImmuneScores have driven the development of personalized immunotherapy strategies for lung cancer, and they can aid in predicting immune resistance, and forecasting immune-related adverse events (irAEs). This review summarizes the prognosis value of immune-related biomarkers and ImmuneScores in immunotherapy and combination therapies for lung cancer. The aim is to provide a foundation for personalized treatment and management of lung cancer, while offering guidance for future research directions in immunotherapy.

查看原文本刊更多论文

肺癌的生物标志物和免疫评分：免疫治疗和联合治疗策略的预测性见解。

肺癌仍然是全世界癌症相关死亡的主要原因。包括化疗、放疗和肿瘤抗血管生成治疗在内的免疫治疗和联合治疗已显示出良好的临床效果，有望成为未来肺癌治疗的关键途径。然而，由于免疫抵抗，免疫治疗仅对一小部分患者有效，而许多其他患者要么最初没有反应，要么随着时间的推移产生耐药性。此外，免疫治疗引起的免疫相关不良事件进一步使治疗结果和预后复杂化。免疫相关生物标志物和免疫评分推动了肺癌个性化免疫治疗策略的发展，它们可以帮助预测免疫抵抗和预测免疫相关不良事件（irAEs）。本文综述了免疫相关生物标志物和免疫评分在肺癌免疫治疗和联合治疗中的预后价值。旨在为肺癌的个性化治疗和管理提供基础，同时为未来免疫治疗的研究方向提供指导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biological Procedures Online 生物-生化研究方法

CiteScore

10.50

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： iological Procedures Online publishes articles that improve access to techniques and methods in the medical and biological sciences. We are also interested in short but important research discoveries, such as new animal disease models. Topics of interest include, but are not limited to: Reports of new research techniques and applications of existing techniques Technical analyses of research techniques and published reports Validity analyses of research methods and approaches to judging the validity of research reports Application of common research methods Reviews of existing techniques Novel/important product information Biological Procedures Online places emphasis on multidisciplinary approaches that integrate methodologies from medicine, biology, chemistry, imaging, engineering, bioinformatics, computer science, and systems analysis.